Menlo Park, CA, January 12, 2026 (Business Wire) -- Inquis Medical closed a $75 million Series C financing from an undisclosed strategic investor to accelerate nationwide commercial expansion of its AVENTUS thrombectomy system and advance its next-generation pipeline. The raise follows a pivotal year in which the company transitioned to a commercial-stage organization, expanded regulatory clearance for pulmonary embolism, and published positive pivotal trial data demonstrat

Billerica, MA, January 8, 2026 (Business Wire) -- Quanterix Corporation appointed Everett Cunningham as President and Chief Executive Officer, effective January 19, 2026, as part of a planned leadership transition. Cunningham joins from Illumina, where he served as Chief Commercial Officer, following earlier commercial leadership roles at Exact Sciences, Quest Diagnostics, GE Healthcare, and Pfizer. The company said it expects to exceed its full-year 2025 revenue and cash g

Boston, MA, January 9, 2026 (PRNewswire) -- Haemonetics Corporation announced the acquisition of Vivasure Medical Limited, a Galway-based medtech company developing next-generation percutaneous vessel closure technology. Vivasure’s PerQseal® Elite system uses a fully bioabsorbable, suture-free patch to close large-bore access sites and has already secured CE Mark approval in Europe, with a U.S. FDA PMA submission completed in 2025. The deal includes €100 million in upfront

Melville, NY, January 12, 2026 (Business Wire) -- Henry Schein, Inc. announced the appointment of Frederick M. Lowery as Chief Executive Officer, effective March 2, 2026, at which point he will also join the Board of Directors. Lowery succeeds Stanley M. Bergman, who will step down after 35 years as CEO and continue as Chairman to support a smooth leadership transition. Lowery brings more than 20 years of healthcare distribution and operational leadership experience, most r

Indianapolis, IN, January 7, 2026 (PR Newswire) -- Eli Lilly and Company announced it will acquire Ventyx Biosciences in an all-cash transaction valued at approximately $1.2 billion, expanding its presence in inflammatory-mediated diseases. The deal brings Ventyx’s clinical-stage portfolio of oral small molecules, including NLRP3 inhibitors designed to address chronic inflammation across cardiometabolic, neurodegenerative, and autoimmune conditions. Lilly will pay $14.00 pe

Tel Aviv and Boston, MA, December 18, 2025 (Business Wire) -- Syremis Therapeutics debuted with a $165 million Series A financing to develop best-in-class medicines for severe mental health conditions, led by Dexcel Pharma and Third Rock Ventures. The funding will support clinical proof of concept for ST-905, a dual M1/M4 muscarinic agonist already in Phase 1 for schizophrenia, and advance ST-901, a novel NMDA antagonist for major depressive disorder and bipolar depression

Boston, MA, December 18, 2025 (Business Wire) -- PureTech Health plc announced that its Board of Directors has appointed Robert Lyne as Chief Executive Officer (CEO) and a member of the Board, effective immediately. Lyne had served as interim CEO since July 2025 and joined PureTech in January 2024 as Chief Portfolio Officer. His leadership priorities include advancing financing for emerging entities such as Celea Therapeutics following recent regulatory progress, while shar

Paris and Emeryville, CA, December 24, 2025 (Reuters) -- Sanofi announced it will acquire U.S.-based Dynavax Technologies in a deal valued at approximately $2.2 billion, adding an approved adult hepatitis B vaccine and a late-stage shingles candidate to its vaccines pipeline. The transaction, expected to close in Q1 2026, follows recent strategic moves by Sanofi to broaden growth beyond its blockbuster asthma treatment Dupixent, including acquisitions of Vicebio and BluePri

Houston, TX, December 17, 2025 (ACCESS Newswire) -- CNS Pharmaceuticals announced a CEO transition, with industry veteran Rami Levin appointed President and Chief Executive Officer, effective January 1, 2026, following the departure of John Climaco. Levin brings nearly three decades of global leadership experience across oncology, neurology, rare diseases, and cell and gene therapy, including scaling organizations, advancing late-stage programs, and raising capital. The boa

New Brunswick, NJ, December 29, 2025 (PR Newswire) -- Johnson & Johnson has completed its $3.05 billion all-cash acquisition of Halda Therapeutics, adding a differentiated oral oncology platform to its Innovative Medicine portfolio. The deal brings HLD-0915, a once-daily oral prostate cancer therapy designed to overcome resistance mechanisms through Halda’s proprietary RIPTAC™ technology. Beyond prostate cancer, the platform also supports earlier-stage programs across breas

San Francisco, CA, December 15, 2025 (Yahoo Finance) -- OpenAI-backed biotech startup Chai Discovery raised $130 million in a Series B financing round, pushing its valuation to $1.3 billion. The round was led by General Catalyst and Oak HC/FT, with participation from Menlo Ventures, OpenAI, Thrive Capital, SV Angel, Emerson Collective, and others, bringing total funding to more than $225 million. Chai develops AI foundation models for drug discovery, and says its latest pla

Yardley, PA, December 5, 2025 (PR Newswire) -- Jubilant Therapeutics announced the appointment of Daniel J. O’Connor as President and Chief Executive Officer, effective December 1, 2025, as the company advances its clinical-stage oncology and autoimmune pipeline. O’Connor brings more than three decades of leadership experience in biotechnology, most recently guiding Ambrx Biopharma through a period of significant value creation that culminated in its acquisition. His prior

Brisbane, CA, December 09, 2025 (Globe Newswire) -- Vera Therapeutics announced the pricing of an underwritten public offering of just over 6.1 million Class A shares at $42.50 per share, generating approximately $261 million in gross proceeds before fees. The company also granted underwriters a 30-day option to purchase up to an additional 920,716 shares, which could further increase the total raise. Proceeds are expected to support Vera’s late-stage clinical development p

Galway, Ireland, December 17, 2025 (Business Wire) -- AVeta Medical announced the appointment of Karen Noblett, M.D., as Chief Executive Officer, marking a leadership transition as the company advances its VITA AV™ platform for genitourinary syndrome of menopause. Noblett joins from Axonics, where she served as Chief Medical Officer and led clinical strategy, regulatory programs, and physician education supporting the global adoption of sacral neuromodulation technologies.

New York, NY, December 17, 2025 (Reuters) -- Medline shares surged 20.7% in their New York debut after the medical supplies company raised $6.26 billion in an upsized initial public offering, valuing the business at roughly $46 billion and making it the largest U.S. IPO since Rivian’s 2021 listing. Backed by Blackstone, Carlyle and Hellman & Friedman, Medline sold 216 million shares at $29 each, cementing the biggest private-equity-backed IPO on record and the largest globa

Tarrytown, NY and Somerville, MA, December 1, 2025 (Globe Newswire) -- Regeneron Pharmaceuticals and Tessera Therapeutics are collaborating to develop TSRA-196, an in vivo Gene Writing therapy targeting alpha-1 antitrypsin deficiency (AATD), a genetic disease affecting lungs and liver in roughly 200,000 people in the U.S. and Europe. The therapy aims to correct the underlying mutation and restore functional protein through a one-time durable treatment. Tessera will lead ini

Baar, Switzerland and Portsmouth, NH, December 3, 2025 (Business Wire) -- Novocure (NASDAQ: NVCR) named Frank Leonard as its new Chief Executive Officer, effective immediately, following the resignation of Ashley Cordova. Leonard, previously Novocure’s President, has spent over 15 years leading global business operations and helping launch the company’s device-based cancer therapies. William Doyle, Executive Chairman, highlighted Leonard’s pivotal role in shaping Novocure’s

St. Paul, MN, November 20, 2025 (PRNewswire) -- Solventum (NYSE: SOLV) will acquire Acera Surgical, a private bioscience company specializing in fully engineered materials for regenerative wound care, for $725 million in cash plus up to $125 million in milestone-based payments. Acera, founded in 2013, markets Restrata® products in the U.S., used to treat complex, hard-to-heal wounds in acute care settings. Read full article here .

New York, December 3, 2025 (PRNewswire) -- Baird Medical appointed Mark Saxton as CEO of its U.S. subsidiary, bringing over 25 years of medtech leadership including experience at NeuroPace, Smith + Nephew, and Covidien. Saxton will lead U.S. operations, driving the expansion of Baird’s minimally invasive Microwave Ablation (MWA) platform. Read full article here .

Chicago, IL, November 24, 2025 (finance yahoo) -- GE HealthCare (GEHC) announced it will acquire Intelerad, a cloud-based medical imaging software leader, in a $2.3 billion all-cash transaction. The acquisition expands GEHC’s cloud and AI-enabled imaging capabilities across inpatient and outpatient settings, supporting its long-term precision care strategy. The deal brings Intelerad’s outpatient expertise into GEHC’s hospital-focused portfolio, creating a more connected ent